The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes

Jul 30, 2025Current atherosclerosis reports

Six New Uses of GLP-1 Receptor Agonists Beyond Diabetes

AI simplified

Abstract

GLP-1 receptor agonists (GLP-1RAs) may induce clinically meaningful weight loss in individuals with overweight or obesity.

  • GLP-1RAs were originally developed for glycemic control in type 2 diabetes but are now being explored for various other health conditions.
  • Research indicates that GLP-1RAs may provide cardiovascular benefits and protect kidney function.
  • They show potential in managing obesity-related conditions such as obstructive sleep apnea and metabolic-associated liver disease.
  • Preliminary data suggest GLP-1RAs could have roles in treating substance use disorders, including alcohol and nicotine dependence.
  • Despite their benefits, GLP-1RAs are associated with side effects and high costs, affecting patient access.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free